Lyra Therapeutics (LYRA) AI Stock Analysis

• Market Cap: $7.91M
• Dividend Yield: N/A
• Average Volume (3M): 871.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: -1.54%
• EPS Growth: -7.20%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -1.44
• Shares Outstanding: 65,880,140
• 10 Day Avg. Volume: 715,656
• 30 Day Avg. Volume: 871,839
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 7.52
• Price to Cash Flow (P/CF): -0.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.00
• Price Target Upside: 1566.67% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

Lyra Therapeutics is currently facing significant financial difficulties, characterized by negative revenue growth, increasing leverage, and negative cash flows. Technical indicators reflect a bearish trend, and the company's valuation is weak due to its unprofitability. These combined factors result in a low overall stock score, highlighting the need for strategic changes to improve its financial and market standing.

Positive Factors

Financial Performance

LYRA reported EPS of $(0.18) versus consensus of $(0.22), showing better than expected financial performance.

Regulatory Progress

The company received written responses from the FDA supporting a Type C meeting for LYR-210 development in CRSwNP patients.

Safety Data

Results from the ENLIGHTEN 1 52-week extension study continue to support the safety of LYR-210.

Negative Factors

Clinical Trial Risks

ENLIGHTEN I missed its primary endpoint, indicating increased risk for the ENLIGHTEN II readout.

Regulatory Uncertainty

There is a current lack of clarity around an approval path for LYR-210 and uncertainty around the outcome of the ENLIGHTEN II trial.

Stock Market Compliance

The company announced plans to implement a reverse stock split to maintain compliance with NASDAQ listing standards.

Lyra Therapeutics Business Overview & Revenue Model

Company Description

Lyra Therapeutics, Inc. (LYRA) is a clinical-stage therapeutics company focused on the development of innovative products for the treatment of ear, nose, and throat (ENT) diseases. The company leverages its proprietary XTreo platform to design and develop drug-eluting implants that deliver medication directly to the affected tissue over an extended period. Lyra's primary focus is on developing solutions for chronic rhinosinusitis, a prevalent condition that lacks optimal treatment options.

How the Company Makes Money

Lyra Therapeutics makes money through the development and commercialization of its proprietary drug-eluting implant products. The company's revenue model primarily hinges on bringing its therapeutic solutions to market, targeting partnerships with pharmaceutical companies for distribution and co-development. Lyra seeks to generate revenue through product sales, licensing agreements, and potential collaborations with other entities in the healthcare and pharmaceutical sectors. Additionally, Lyra may engage in strategic partnerships or joint ventures to expand its market reach and expedite the commercialization of its therapies. Revenue generation is largely dependent on successful clinical trials, regulatory approvals, and market adoption of its products.

Lyra Therapeutics Financial Statement Overview

Summary

Lyra Therapeutics is facing financial challenges, with consistent losses and negative cash flows. The biotechnology industry often requires substantial investment, but the company's high leverage and shrinking equity base pose risks. While there are strengths in operational cash efficiency, overall financial health is concerning, necessitating strategic adjustments to improve profitability and reduce reliance on external funding.

Income Statement

Lyra Therapeutics has experienced a decrease in total revenue from $1,558,000 in 2023 to $1,534,000 in 2024. The net profit margin remains negative, reflecting ongoing losses. Despite revenue growth in prior years, the company struggles with high operating losses, as evidenced by the negative EBIT and EBITDA margins.

Balance Sheet

The company's debt-to-equity ratio has increased, indicating higher leverage, but remains manageable. Stockholders' equity has decreased significantly, suggesting potential financial instability. Despite a high equity ratio, the reduction in total assets and equity raises concerns about long-term sustainability.

Cash Flow

Lyra has a negative free cash flow, indicating cash outflows exceeding inflows. Operating cash flow remains negative, though there is a high operating cash flow to net income ratio, reflecting cash efficiency in operations. However, the reliance on financing activities for cash inflows indicates a need for external funding.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.47M	1.53M	1.56M	1.36M	285.00K	0.00
	Gross Profit
-12.01M	1.53M	1.56M	296.00K	-716.00K	-95.00K
	EBIT
-101.42M	-96.35M	-67.12M	-56.31M	-43.62M	-22.21M
	EBITDA
-67.04M	-96.35M	-65.25M	-53.92M	-42.61M	-22.11M
	Net Income Common Stockholders
-97.61M	-93.44M	-62.68M	-55.28M	-42.41M	-22.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.89M	40.58M	102.75M	97.89M	45.75M	74.59M
	Total Assets
0.00	66.35M	142.60M	109.97M	54.87M	80.83M
	Total Debt
0.00	34.38M	26.88M	2.22M	1.45M	2.44M
	Net Debt
23.89M	-6.20M	4.53M	-30.33M	-44.29M	-72.15M
	Total Liabilities
0.00	54.75M	53.18M	29.21M	20.55M	6.34M
	Stockholders Equity
23.28M	11.59M	89.42M	80.75M	34.32M	74.49M
Cash Flow		Free Cash Flow
-80.90M	-72.35M	-64.35M	-43.55M	-29.20M	-22.92M
	Operating Cash Flow
-77.72M	-70.01M	-63.30M	-43.38M	-25.82M	-21.14M
	Investing Cash Flow
49.81M	80.31M	-12.58M	-65.01M	-3.38M	-1.77M
	Financing Cash Flow
27.45M	8.53M	65.69M	96.26M	359.00K	87.70M

Lyra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYRA, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.18, and below the 200-day MA of 0.24, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 22.56 is Positive, neither overbought nor oversold. The STOCH value of 5.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYRA.

Lyra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRTX	64 Neutral	$124.50B	―	-3.15%	―	11.64%	-114.72%
ALNY	55 Neutral	$35.12B	―	-414.62%	―	22.97%	38.54%
IONS	49 Neutral	$4.80B	―	-93.03%	―	-10.48%	-18.79%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
CRSP	46 Neutral	$2.92B	―	-19.20%	―	-89.95%	-123.71%
LYRA	42 Neutral	$7.91M	―	-184.99%	―	-1.54%	-7.20%
FGEN	42 Neutral	$30.29M	―	60.38%	―	5.59%	83.59%

Lyra Therapeutics Corporate Events

Lyra Therapeutics Pursues ENLIGHTEN 2 Trial for LYR-210

Lyra Therapeutics has announced a corporate presentation detailing their ongoing ENLIGHTEN 2 Phase 3 trial for LYR-210, targeting the treatment of CRS. Despite previous setbacks, including the failure of the ENLIGHTEN 1 trial to meet its primary endpoint, the company is continuing its efforts with updated trials and anticipates results in the second quarter of 2025. The announcement highlights Lyra’s challenges such as funding needs and market acceptance, but also emphasizes the potential of LYR-210 in aligning with ENT practices and addressing unmet needs in CRS treatments.